Back to the Top
The following message was posted to: PharmPK
Dear Colleagues,
I am a medical doctor - neurologist - with some background in PK/PD
modelling and simulation. I am working with a group of oncologists
interested in TDM of cytotoxic agents, especially methotrexate. Does anyone
know about compartmental or non-compartmental models and population values
of parameters of this drug and other cytotoxic agents?
Thank you in anticipation,
Alexandru Floares, M.D., PhD
alexf.-at-.iasi.mednet.ro
ander.-at-.uaic.ro
Back to the Top
The following message was posted to: PharmPK
There is a good review of methotrexate written by Evans, WE in his book,
Applied Pharmacokinetics-Principles of Therapeutic Drug Monitoring.
Supong
Back to the Top
The following message was posted to: PharmPK
Look at :
"Bayesian estimation and prediction of clearance in high-dose methotrexate
infusions" A. Iliadis, M. Bachir-Raho, R.Bruno, and R.Favre
J of Pharmacokinetics and Biopharmaceutics, 13, 1985, 101-115
Population matrix are published for taxotere, VP16, doxorubicin,...
Dr Brigitte Tranchand
Lab Pharmacocin=E9tique
Centre L=E9on-B=E9rard
69373 Lyon Cedex 8
=46rance
Tel : 33 4 78 78 27 59
=46ax : 33 4 78 78 27 58
e-mail : tranchan.aaa.lyon.fnclcc.fr
Back to the Top
Dear Dr Floares:
In our Pharmacy Department we have been working for 18 years with methotrexate
in children and adults and we have defined our own high-risk MTX concentrations
.. We have also studied the relationship between exposition to methotrexate and
response in children with osteosarcoma and we have been able to establish an
AUC to reach in order to improve survival in osteosarcoma .
If you want any further information about this, do not doubt in contact us.
Sincerely,
Azucena Aldaz.
Back to the Top
The following message was posted to: PharmPK
Alexandru,
Ken Bischoff and Robert Dedrick in the US developed a number of PK and
PBPK models for methotrexate. Below are the references I have at hand.
Bischoff KB.Some fundamental considerations of the applications of
pharmacokinetics to cancer chemotherapy. Cancer Chemother Rep. 1975
Jul-Aug;59(4):777-93.
Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA. Methotrexate
pharmacokinetics.
J Pharm Sci. 1971 Aug;60(8):1128-33.
Zaharko DS, Dedrick RL, Bischoff KB, Longstreth JA, Oliverio VT.
Methotrexate tissue distribution: prediction by a mathematical model.
J Natl Cancer Inst. 1971 Apr;46(4):775-84.
Bischoff KB, Dedrick RL, Zaharko DS. Preliminary model for
methotrexate pharmacokinetics. J Pharm Sci. 1970 Feb;59(2):149-54.
Regards
Alex MacDonald
Dr.A.J.MacDonald
Senior Scientist
Computational Toxicology Unit
Health and Safety Laboratory
Broad Lane
Sheffield
S3 7HQ
UK
Tel. +44 (0)114 2892902
Fax. +44 (0)114 2892500
email. Alex.MacDonald.aaa.HSL.gov.uk
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (david@boomer.org)